Pelthos Therapeutics PTHS
NYSE PTHS
$20.66 -0.35 (-1.67%)
As of: Oct 1, 2026 · 3:53 PM EDT

Pelthos Therapeutics (PTHS) Return on Equity [ROE] (2024 - 2026)

Updated

Pelthos Therapeutics' Return on Equity [ROE] was -972.61% in Q2 2026, down 744.14 percentage points from the prior quarter.

Analysis

Pelthos Therapeutics (PTHS) Return on Equity [ROE] (2024 - 2026) Analysis & Trends

For FY2025, Return on Equity [ROE] at Pelthos Therapeutics came in at -239.55%.

  • The Q2 2026 figure marks the lowest quarterly Return on Equity [ROE] since Q2 2024.
  • Per Business Quant data, PTHS's Return on Equity [ROE] in the three quarters before Q2 2026 was -228.47% (Q1 2026), -89.19% (Q4 2025) and -91.12% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 25.32%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 7.21%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 84.40%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 21.39%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 83.75%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -18.38%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 4.97%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 22.24%
10 Pelthos Therapeutics 79.95 Mn -8.44 Mn 11.99 Mn -972.61%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -972.61%
Mar 31, 2026 -228.47%
Dec 31, 2025 -89.19%
Sep 30, 2025 -91.12%
Jun 30, 2024 -2,070.79%
API Access

Pelthos Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=PTHS&period=max&api_key=YOUR_API_KEY